CD274 and non-small cell lung carcinoma: Atezolizumab, a PD-L1-targeted mAb, was recently approved for therapy of locally advanced or metastatic urothelial malignancy with cisplatin ineligibility and showed favorable outcome for advanced NSCLC [48,49].